Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy B Jones

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic SyndromeGheath Alatrash, Peter F Thall, Benigno C Valdez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar, Borje S Andersson, Daniel Couriel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 31, 2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesYago Nieto, Peter Thall, Ben Valdez, et al.
Bone Marrow Transplantation|January 5, 2021
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHDRohtesh S Mehta, Roland Bassett, Gabriela Rondon, et al.
Leukemia & Lymphoma|October 13, 2011
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplantStefan O Ciurea, Rima M Saliba, Nelson Hamerschlak, et al.
Haematologica|May 6, 2021
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysisYago Nieto, Stephen Gruschkus, Benigno C Valdez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
The New England Journal of Medicine|December 14, 2012
Cord-blood engraftment with ex vivo mesenchymal-cell cocultureMarcos de Lima, Ian McNiece, Simon N Robinson, et al.
Blood|March 18, 2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantationUday Popat, Rohtesh S Mehta, Katayoun Rezvani, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic SyndromeGheath Alatrash, Peter F Thall, Benigno C Valdez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar, Borje S Andersson, Daniel Couriel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 31, 2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesYago Nieto, Peter Thall, Ben Valdez, et al.
Bone Marrow Transplantation|January 5, 2021
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHDRohtesh S Mehta, Roland Bassett, Gabriela Rondon, et al.
Leukemia & Lymphoma|October 13, 2011
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplantStefan O Ciurea, Rima M Saliba, Nelson Hamerschlak, et al.
Haematologica|May 6, 2021
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysisYago Nieto, Stephen Gruschkus, Benigno C Valdez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
The New England Journal of Medicine|December 14, 2012
Cord-blood engraftment with ex vivo mesenchymal-cell cocultureMarcos de Lima, Ian McNiece, Simon N Robinson, et al.
Blood|March 18, 2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantationUday Popat, Rohtesh S Mehta, Katayoun Rezvani, et al.
Pageof 7